Table IV.

Serious adverse events within 1 year of recruitment.

Events	Aflibercept (n=40)	Ranibizumab (n=40)	P-value
Endophthalmitis	0 (0.0)	0 (0.0)	–
Ocular inflammation	1 (2.5)	1 (2.5)	1.000
Retinal detachment or tear	0 (0.0)	1 (2.5)	0.314
Vitreous hemorrhage	1 (2.5)	2 (5.0)	0.556
Injection-associated cataract	1 (2.5)	1 (2.5)	1.000
Elevation of intraocular pressure	6 (15.0)	5 (12.5)	0.745
Non-fatal myocardial infarction	1 (2.5)	0 (0.0)	0.314
Non-fatal stroke	0 (0.0)	1 (2.5)	0.314
Death from any cause	0 (0.0)	0 (0.0)	–
Gastrointestinal events	9 (22.5)	7 (17.5)	0.576
Renal events	6 (15.0)	5 (12.5)	0.745
Hypertension	5 (12.5)	5 (12.5)	1.000

Values are expressed as n (%).